Ipatasertib
- Generic Name
- Ipatasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32ClN5O2
- CAS Number
- 1001264-89-6
- Unique Ingredient Identifier
- 524Y3IB4HQ
- Background
Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Targeted Treatment Provides ORR and PFS Benefit in Pretreated Metastatic Solid Tumors
Targeted treatment based on mutational status showed higher overall response rate (ORR) and progression-free survival (PFS) vs standard of care (SOC) in pretreated metastatic solid tumors, according to the phase 2 ROME trial. ORR was 17.0% in the targeted treatment arm vs 9.5% in the SOC arm (P = .026). Median PFS was 3.7 months in the targeted arm vs 2.8 months in the SOC arm (HR 0.64; 95% CI, 0.51-0.80; P < .001).
Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor
References detail lymphoid neoplasm classification, genetic subtypes of diffuse large B cell lymphoma, molecular classification and treatment, and targeted therapies like polatuzumab vedotin and AKT inhibitors in lymphoma treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath